<DOC>
	<DOCNO>NCT01999920</DOCNO>
	<brief_summary>The purpose study determine whether Vilazodone ( Viibryd ) , SSRI 5HT1a receptor agonist , effective treat Adult Separation Anxiety Disorder 12-week treatment course .</brief_summary>
	<brief_title>Vilazodone Separation Anxiety Disorder</brief_title>
	<detailed_description>In randomized clinical trial , 40 adult principal diagnosis Adult Separation Anxiety Disorder ( ASAD ) major depression substance abuse disorder randomize 12 week treatment vilazodone ( flexibly dose ) match pill placebo . Outcome assess respect symptomatic improvement , quality life , adverse event safety .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Anxiety , Separation</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Vilazodone Hydrochloride</mesh_term>
	<criteria>Current primary ( clinically significant ) diagnosis DSM5 ASAD Able give consent , fluent English Past current DSMIV diagnosis psychotic disorder ; organic mental disorder cognitive disorder ; bipolar disorder ; antisocial personality disorder . Current MDD moderate great severity . Any current primary Axis I disorder . Recent history ( past 3 month ) substance alcohol abuse dependence ( nicotine caffeine ) Suicidal ideation behavior ( past year ) pose significant danger subject Medical illness could significantly increase risk vilazodone treatment interfere assessment diagnosis treatment response , include organic brain impairment stroke , CNS tumor , demyelinate disease ; renal impairment ; diabetes mellitus Current past history seizure disorder ( except febrile seizure childhood ) History nonresponse â‰¥ 2 serotonergic reuptake inhibitor antidepressant ( SSRIs and/or SNRIs ) treatment ASAD adequate treatment trial ( adequate treatment define least 8 week adequate dose [ ] base approve package insert recommendation ) Currently take medication effective patient 's ASAD For patient take ineffective psychoactive drug herbal remedy , inability tolerate unwillingness accept drugfree period prior begin study 2 week 5 halflives ( whichever longer ) begin study treatment , ever treat depot antipsychotic . Fluoxetine washout period least 5 week . Requiring concomitant treatment prohibit medication , supplement , herbal remedy , except zolpidem , zolpidem extend release insomnia , may continue provided medication use consistent manner 4 week prior randomization History intolerance hypersensitivity vilazodone , SNRIs SSRIs History light therapy , electroconvulsive therapy , vagus nerve stimulation , transcranial magnetic stimulation , experimental procedure central nervous system disorder within 6 month begin study Pregnancy , lactation ; woman childbearing potential , use effective birth control method ( e.g. , oral contraceptive double barrier method ) duration study Current formal psychotherapy initiate within 3 month begin study . This include : psychodynamic , cognitivebehavioral interpersonal therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Adult separation anxiety disorder</keyword>
	<keyword>ASAD</keyword>
</DOC>